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Abstract: During a global research expedition, more than five hundred marine bacterial 
strains capable of inhibiting the growth of pathogenic bacteria were collected. The purpose 
of the present study was to determine if these marine bacteria are also a source of 
compounds that interfere with the agr quorum sensing system that controls virulence gene 
expression in Staphylococcus aureus. Using a gene reporter fusion bioassay, we recorded agr 
interference as enhanced expression of spa, encoding Protein A, concomitantly with reduced 
expression of hla, encoding α-hemolysin, and rnaIII encoding RNAIII, the effector molecule 
of agr. A marine Photobacterium produced compounds interfering with agr in S. aureus 
strain 8325-4, and bioassay-guided fractionation of crude extracts led to the isolation of 
two novel cyclodepsipeptides, designated solonamide A and B. Northern blot analysis 
confirmed the agr interfering activity of pure solonamides in both S. aureus strain 8325-4 
and the highly virulent, community-acquired strain USA300 (CA-MRSA). To our 
knowledge, this is the first report of inhibitors of the agr system by a marine bacterium. 
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1. Introduction  
Microorganisms are an attractive source of new natural products with antimicrobial properties [1,2], 
and the marine environment constitutes a prolific resource of bioactive microorganisms [3–5]. Many 
marine microenvironments stimulate the production of specific metabolites as a response to environmental 
factors [6]. It is likely that some of these metabolites mediate both intra- and interspecies microbial 
interactions, and can be seen as potential new scaffolds for development of drug lead candidates [6,7]. 
The increasing problem of antibiotic resistance among human pathogens highlights the need for novel 
therapeutic strategies [8]. The search for new avenues in microbial control has therefore been extended 
from traditional bacteriostatic or bacteriolytic compounds to compounds that target, for example, 
quorum sensing (QS) pathways [9–11]. Quorum sensing inhibitors (QSI) do not necessarily kill or 
inhibit the growth of a pathogen but rather modulate microbial phenotypes, for example by attenuating 
virulence [12,13]. In vivo studies with QS inhibitory compounds demonstrated how these can be used 
to slow the spread of infection [14] or enhance the clearance of pathogens from infected tissue [10]. 
Staphylococcus aureus is one of the main causes of nosocomial infections, and methicillin-resistant 
S. aureus (MRSA) are emerging at an alarming rate [15,16]. The virulence of S. aureus is ascribed to a 
number of virulence factors, including extracellular toxins such as α-hemolysin encoded by hla, and 
cell surface adhesion factors such as Protein A encoded by spa [17]. Their expression is coordinated 
through several key regulators, of which the agr (accessory gene regulator) QS system is central [18]. 
This system is a classical two-component system with a sensor histidine kinase, AgrC, and a response 
regulator, AgrA, in addition to AgrB and AgrD which are responsible for the production of the quorum 
sensing signal [19,20]. agr-dependent QS is mediated via autoinducing peptides (AIP), 16-membered 
thiolactone macrocycles carrying a peptide tail that control virulence gene expression through the 
effector molecule RNAIII [21,22]. Structure-activity relationship studies (SAR) demonstrated that 
while the tail of the AIP is essential for agr activation [19,23], the macrocyclic ring is responsible for 
antagonistic activity [23]. This has led to the synthesis of global inhibitors based on truncated 
AIPs [23,24]; however, there are only few reports of natural antagonists of this system [24–27]. 
Nielsen et al. [28] recently developed a screening assay based on S. aureus lacZ reporter fusion strains, 
where the effect of compounds or extracts on expression of three key virulence genes (spa, hla, and 
rnaIII) and hence potential interference with the agr locus can be assessed. Subsequently, the assay 
was used to identify two xanthones as novel quorum sensing interfering compounds in S. aureus [28].  
We recently established a global collection of marine bacteria with antibacterial activity [29]. The 
purpose of the present study was to determine if this strain collection also harbored organisms that 
produced other types of bioactive compounds and we screened pure cultures, crude extracts, and purified 
secondary metabolites from the collection for potential inhibitors of the agr system. One of the bacterial 
families we investigated was the Vibrionaceae. These bacteria are ubiquitous in marine and brackish 
environments and often associated with marine organisms [30]. The Vibrionaceae consist of seven 
genera, with the majority of species belonging to the Vibrio and Photobacterium genera. Vibrio spp. can 
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be pathogenic to humans [31–33] or marine animals [30], but also occur in the commensal microflora of 
zooplankton [30] or live as bioluminescent symbionts with squid or fish [34–36]. The Photobacterium 
genus similarly comprises symbiotic [37,38] and pathogenic species [39–41]. Members of the 
Vibrionaceae produce broad-range inhibitory compounds [7,29]; however, only few of the antibacterial 
compounds have been isolated to date [42]. Antimicrobial compounds from Vibrio species include the 
pyrrolidinediones andrimid [43–45] and moiramide B [46] that inhibit fatty acid synthesis [47]. In 
addition, we recently reported the production of the potent pyrrothine antibiotic holomycin by a marine 
Photobacterium [45]. 
Herein, we report the isolation and chemical investigation of two novel depsipeptides produced by 
that same Photobacterium strain. The compounds, designated solonamides A and B, inhibit the agr QS 
system of S. aureus and therefore interfere with its virulence gene expression. This indicates that 
marine bacteria are a source of novel chemistry with potential use in antibacterial therapy. 
2. Results and Discussion  
2.1. Identification of QS Inhibitors from Photobacterium sp. 
In an initial search for antimicrobial compounds we isolated strain S2753 related to Photobacterium 
halotolerans [29]. Subsequently, the known antibiotic, holomycin, was identified as responsible for its 
growth inhibitory activity [45]. When investigating ethyl acetate extracts of S2753 in an agar diffusion 
assay monitoring expression of the S. aureus virulence genes hla, rnaIII, and spa [28], we observed an 
increased expression of spa and decreased expression of hla and rnaIII. The inverse effect of the extracts 
on spa and hla/rnaIII expression, respectively, indicates the presence of at least one compound that 
interferes with the S. aureus agr QS system [28]. Secondary screening of the extract by explorative 
solid-phase extraction (E-SPE) [48] detected the potential QSI activity in a fraction that did not inhibit 
growth of S. aureus or V. anguillarum (data not shown). Bioassay-guided fractionation by diol and  
C-18 columns resulted in the isolation of two compounds active in the S. aureus agar diffusion assay 
(Figure 1). The activity of the pure compounds matched the initial activity of the extract, confirming 
that these compounds are responsible for the observed changes in gene expression. 
Figure 1. Effect of solonamides (A and B) on hla, rnaIII and spa expression. Solonamides 
(5 mg mL−1) were added to wells in TSA plates containing the 8325-4 derived lacZ reporter 
strains PC322 (hla::lacZ), SH101F7 (rnaIII::lacZ), or PC203 (spa::lacZ). Incubation time 
was 15 h for plate I and II, and 35 h for plate III (plate numbering indicated with white 
letters). Solonamide B tested in two wells. 
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2.2. Structural Elucidation of the Solonamides 
The solonamides were isolated as white powder with respective molecular formulas C30H46N4O6 (A) 
and C32H50N4O6 (B) as determined by HRMS (1 ppm mass accuracy). Analysis of NMR data 
characterized the structures of the solonamides as cyclodepsipeptides consisting of four amino acids 
and a 3-hydroxy fatty acid (Figure 2). The amino acid composition was elucidated as alanine, 
phenylalanine, and two leucines for both peptides based on DQF-COSY and HSQC NMR data. 
Figure 2. Structures of solonamides A and B produced by Photobacterium sp. strain S2753 
and structure of natural group I AIP [21]. 
A B 
 
I 
The spin systems of the amino acids were confirmed through strong and unambiguous H2BC 
correlations [49] and the carbonyl signals assigned by HMBC correlations. Through careful inspection of 
the DQF-COSY and H2BC NMR data, solonamide A was found to contain a 3-hydroxyhexanoic acid 
(Hha), while solonamide B contained a 3-hydroxyoctanoic acid (Hoa). Long-range HMBC and NOESY 
correlation data allowed the sequence of amino acids to be established as fatty acid-Phe-Leu-Ala-Leu 
(Figure in Supplementary Information). This was corroborated by MS-MS experiments giving the 
exact molecular formula of the fragments (2 ppm mass accuracy, see Supplementary Information). The 
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in Leu and a weak NOESY correlation from H-3 to the Leu amide and Hα protons. In total, this 
accounted for the ten degrees of unsaturation resulting from the macrocyclic ring, five carbonyls, and 
the phenyl group. 
The absolute configurations of the individual amino acids were established by acid hydrolysis and 
Marfey’s method with UHPLC analysis. Both peptides were found to contain L-Phe, D-Ala, and an 
enantiomeric pair of L-Leu and D-Leu. Acid hydrolysis of the reduced linear peptides and subsequent 
Marfey’s derivatization specified the stereochemistry of the two Leu, exchanging the L-Leu peak  
(RT 3.77 min) with a new peak (RT 3.73 min), attributable to the corresponding alcohol. Thus, L- and  
D-stereochemistry was assigned as fatty acid-L-Phe-D-Leu-D-Ala-L-Leu in both solonamide A and B.  
The absolute configuration of the fatty acid was established by NMR spectroscopic analysis of the 
1H and 19F chemical shift differences (ΔδSR) in the (R)- and (S)-Mosher’s esters analysis of solonamide A 
and B. The absolute stereochemistry of C-3 in the 3-hydroxy fatty acid was established as (R) in both 
depsipeptides (Figure 3). 
Figure 3. Distribution of the Δδ values (ppm) calculated for the (a) 3-hydroxyhexanoic 
acid (Hha) and (b) 3-hydroxyoctanoic acid (Hoa) in the (R)- and (S)-Mosher’s esters. 
 
(a) 
 
(b) 
The yield of solonamides was up to 10 mg L−1, which is a high organic yield compared to that of 
other γ-proteobacteria [50,51]. This suggests that they could be storage compounds accumulated 
during growth. However, the solonamides were also produced on a chitin based minimal medium 
(Supplementary Information) which indicated that these compounds may be produced in the natural 
habitat of vibrios, such as chitinous zooplankton. In addition, D-alanine and L-leucine are incorporated 
in the structure; amino acids that are not present in the laboratory medium. Thus, the Photobacterium 
seems to produce these specific stereoforms rather than incorporating the available amino acids.  
2.3. Production of Solonamides by Related Photobacterium Strains 
To test whether the solonamides are also produced by strains related to our Photobacterium isolate, 
we compared strain S2753 with P. halotolerans LMG 22194T, P. rosenbergii LMG 22223T, and 
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P. angustum S14 [52]. None of these strains produced solonamides (as confirmed by LC-UV/MS), and 
none affected virulence gene expression in the gene-reporter agar diffusion assay. None of the three 
strains inhibited growth of V. anguillarum, and holomycin, the antibiotic of S2753 [45], was not detected.  
To the best of our knowledge, only two species of Photobacterium have been investigated for  
their secondary metabolites so far [51,53,54]. Oku et al. [51] isolated unnarmicin A and C from a 
marine Photobacterium strain MBIC06485 related to P. leiognathi. Like the solonamides, unnarmicin 
A and C consist of four amino acids (L-Phe, L-Leu, D-Phe, L-Leu) and a 3-hydroxyoctanoic and  
3-hydroxyhexanoic fatty acid, respectively. The finding of the unnarmicins in another marine 
Photobacterium sp. indicates that production of such peptides could be a common feature in this group 
of bacteria, despite the absence of solonamides in any related strains that we investigated.  
2.4. Solonamides Interfere with agr 
To verify that the purified solonamides do in fact cause transcriptional changes in virulence gene 
expression and to assess if the effect is strain specific, we isolated mRNA from S. aureus 8325-4 and 
the community-acquired strain, USA300 at different stages of growth following solonamide exposure 
and monitored gene expression by Northern blot analysis. Solonamide B dramatically reduced the 
expression of both hla and rnaIII while increasing expression of spa, strongly indicating that the 
compound interferes with agr regulation (Figure 4). The decreased expression of rnaIII was even more 
pronounced in the highly virulent USA300 strain where high agr activity is suspected to be a main 
contributor to the virulence of the strain [55,56]. The solonamides did not affect the growth rate of the 
liquid S. aureus cultures. Solonamide A was able to increase spa expression, but caused only a marginal 
reduction of hla and rnaIII expression in both 8325-4 and USA300. The discrepancy between the 
Northern blot analysis and the agar diffusion assay (mainly with regard to hla) may be rooted in the 
much higher concentrations of solonamides that are used in the agar diffusion assay as compared to the 
Northern blot analysis. Also, the Northern blot analysis directly monitors the amount of mRNA shortly 
after solonamide addition, whereas the agar diffusion assay relies on the accumulation of β-galactosidase 
enzyme over a period of 15 or 35 h.  
The structural similarity of the solonamides and the AIPs (Figure 2) suggest that they may  
be competitive inhibitors of the agr system. Unlike the AIPs, the solonamides are cyclized through a  
3-hydroxy fatty acid forming a lactone rather than a thiolactone. However, synthetic lactone and 
lactam variations of natural AIPs have been found to have antagonistic activity [19,23,57], which our 
study corroborates. While inhibition of agr by AIPs is more tolerant of sequence and structural 
diversity than is activation [23], Mayville et al. [14] found that the presence of the hydrophobic leucine 
and phenylalanine residues is important for the inhibition of the agr response. Both solonamides 
contain a leucine and phenylalanine; however, the reduced activity of solonamide A indicates that the 
overall hydrophobicity of the depsipeptides affected by the varying length of the fatty acid moiety 
might be an important factor influencing activity.  
The solonamides are the first reported antagonists produced by a natural source with a structure 
resembling that of native S. aureus AIPs. Kiran et al. (2008) [25] identified hamamelitannin from 
Hamamelis virginiana (witch hazel) as an inhibitor of RNAIII and δ-hemolysin production in S. aureus 
8325-4, USA300, and clinical S. epidermidis isolate MH. Also, ambuic acid from an unidentified fungal 
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strain was found to attenuate agr [26].Given the relatively low abundance of staphylococci in the 
marine environment, it seems unlikely that the Photobacterium sp. S2753 produces solonamides as 
part of a deliberate strategy to interfere with this specific type of bacteria. However, the solonamides 
might be targeted at other Gram-positive bacteria in the marine environment, such as bacilli and 
actinobacteria, though little is known about quorum sensing pathways in marine Gram-positive 
bacteria. A large number of different QS systems have been characterized from Gram-negative 
bacteria in the marine environment [57–62]. We speculate that the solonamides could also affect such 
systems despite sharing little structural similarity to agonists and antagonists of the systems identified 
to date [63]. Acylated homoserine lactones, the most widely researched type of QS molecules in  
Gram-negatives, can serve as both agonists and antagonists in different systems [27], and thus the 
solonamides may also serve as quorum sensing signals for the Photobacterium itself. However, we did 
not detect solonamides or compounds with similar QSI activity in any of the related strains. 
Figure 4. Effect of solonamide A and B on virulence gene expression in S. aureus strain 
8325-4 [18] and USA300 [55] examined by Northern blot analysis. Solonamides were added 
to exponentially growing cultures at OD600 = 0.4, and RNA was purified at OD600 = 0.7 and 
1.7. The RNA was reacted with probes recognizing hla, rnaIII, and spa, respectively. 
Solonamide B tested in duplicates. DMSO was used as negative control. 
 
Our findings suggest that quorum sensing inhibition could be an alternative therapeutic strategy for 
treatment of MRSA S. aureus infections; however, the effect in an in vivo infection model needs to be 
tested. Many genes are under QS control both in Gram-positive and Gram-negative bacteria, and thus 
it is not a simple drug target [64,65]. For example, biofilm formation in S. aureus has been linked to 
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low QS activity [66], and so there is a risk that the use of QS inhibitors could lead to decreased 
susceptibility of traditional antibiotics. Also, it is still unknown how QS inhibition will affect the 
overall fitness of a pathogen under in vivo conditions and thus pose a selective pressure for 
development of resistance [67] or enhanced virulence [68,69]. 
3. Experimental Section 
3.1. Isolation and Identification of Strain S2753 
Bacterial strain S2753 was isolated from a mussel surface collected in the tropical Pacific (9.1°S 
156.8°E) during the Danish Galathea 3 expedition [29]. S2753 was assigned to the Vibrionaceae by 
16S rRNA gene sequence similarity [29] and identified as being closely related to Photobacterium 
halotolerans based on recA and rpoA gene sequences, with homologies of 87% (recA) and 94% 
(rpoA) [45]. BLAST analyses showed that other closely related species were Photobacterium rosenbergii 
and Photobacterium angustum S14 [52].  
3.2. Initial Screening for Anti-Virulence Compounds 
S2753 was cultured in each 30 mL of (i) marine minimal medium (MMM) [70] containing 0.4% 
glucose and 0.3% casamino acids; (ii) Marine Broth 2216 (MB; Difco 2216); (iii) Sigma Sea Salts 
(SSS; Sigma S9883; 40 g L−1) containing 0.4% glucose and 0.3% casamino acids, and (iv) MMM 
containing 0.2% colloidal chitin [71,72] to investigate the best conditions for production of antibacterial 
compounds. All cultures were incubated aerated (200 rpm) for 72 h at 25 °C. All cultures were extracted 
with an equal volume of ethyl acetate (EtOAc). The extract was evaporated under nitrogen until 
dryness and redissolved in 300 μL 80% v/v ethanol (EtOH) in water. 20 μL of the extract was tested in 
an agar diffusion assay where expression from promoters of hla, rnaIII, and spa is monitored [28].  
For further screening, the culture broth of S2753 grown in MMM (1 L, 72 h, 25 °C, 100 rpm) was 
extracted directly with sterile Diaion HP20SS (12 g L−1, 24 h) (Sigma-Aldrich, St. Louis, MO). The 
resin was filtered off and washed with 80% (v/v) acetonitrile (MeCN)/water (300 mL) and the extract 
evaporated until dryness on a rotary evaporator. From this extract, 10 mg dry material was subjected to 
an explorative solid-phase extraction (E-SPE) protocol [48]. This yielded 15 fractions for re-testing in the 
agar diffusion assay as described above. The E-SPE fractions were also tested for antibacterial activity 
against Vibrio anguillarum strain 90-11-287 and S. aureus 8325 in a well diffusion agar assay [73].  
3.3. Isolation and Structural Elucidation of Solonamide A and B 
Using 10 L glass fermentors, S2753 was cultured in 5 × 4 L SSS (iii, above) containing 0.4% glucose 
and 0.3% casamino acids (25 °C, 72 h, 100 rpm) as this medium gave comparable yields to that of 
MMM (i) but at a lower cost. The broth was extracted directly with Diaion HP20SS (12 g L−1) as 
described above. The extract (3.4 g) was redissolved in EtOAc, absorbed onto 5 g Isolute diol 
(Biotage, Uppsala, Sweden), and added to a glass column with pure diol (95 g). A total of 12 fractions 
were collected from the diol column (100 g, 20 × 350 mm) ranging from heptane, dichlormethane 
(DCM), EtOAc, to pure methanol (MeOH), running under gravity. The fractions containing the QSI 
compounds (fraction 5, 20:80 (v/v) EtOAc/DCM and fraction 6, 40:60 (v/v) EtOAc/DCM) were 
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separated on Sepra ZT C18 (Phenomenex, Torrance, CA)(10 g SNAP) on an Isolera automated flash 
system (Biotage) using a MeCN/water gradient 25–75% over 20 min (12 mL min−1). Pure compounds 
were obtained directly: Solonamide A (17 mg) and B (201 mg). Activity of pure compounds was tested 
in the agar diffusion assay as described above (20 μL per well), with a final concentration of compounds 
of 5 mg mL−1 in dimethyl sulfoxide (DMSO).  
NMR spectra were recorded on a Varian Unity Inova 500 MHz spectrometer equipped with a 5 mm 
probe using standard pulse sequences. The signals of the solvent were used as internal references  
(δH 2.49 and δC 39.5 ppm for DMSO). Carbonyl shifts were confirmed with 13C 1D on a Bruker 
Avance 800 MHz spectrometer with a 5 mm TCI cryoprobe at the Danish Instrument Center for NMR 
Spectroscopy of Biological Macromolecules. 
LC-MS and LC-MS/MS analyses were performed on a maXis quadrupole time of flight mass 
spectrometer (Bruker Daltonics, Bremen, Germany) equipped with an electrospray (ESI) ion source. 
The MS was connected to an Ultimate 3000 UHPLC system (Dionex, Sunnyvale, CA) equipped with a 
diode-array detector. Separation was performed at 40 °C on a 150 mm × 2.1 mm ID, 2.6 µm Kinetex 
C18 column (Phenomenex) using a linear water/MeCN (both buffered with 20 mM formic acid) gradient 
starting from 15% MeCN and increased to 100% in 13 min at a flow of 0.4 mL min−1. The MS and 
MS/MS experiments were performed in ESI+ with a data acquisition range of m/z 100–1200 with 
collision energy of 27 V. The MS was calibrated using sodium formate automatically infused prior to 
each analytical run, providing a mass accuracy of below 1 ppm in MS mode and 2 ppm in MS/MS mode.  
The absolute configuration of the amino acids were found using acid hydrolysis (6 M HCl,  
110 °C, 20 h) [74] and derivatisation with Marfey’s reagent (1-fluoro-2,4-dinitrophenyl-5-L-alanine  
amide, FDAA, Sigma-Aldrich) following the protocol by Bonnard et al. [75]. Ultra-high liquid 
chromatography-diode array (UHPLC-UV) analyses of the amino acids were done on a Dionex RSLC 
Ultimate 3000 (Dionex) equipped with a diode-array detector. Separation was obtained on a Kinetex 
C18 column (150 × 2.10 mm, 2.6 μm, Phenomenex) maintained at 60 °C using a linear gradient starting 
from 25% MeCN in water (both buffered with 50 ppm TFA) increasing to 27% MeCN over 6 min at a 
flow rate of 0.8 mL min−1. Retention times of the FDAA amino acid derivatives used as standards were 
as follows (maximum standard deviation ± 0.002 min): FDAA (1.50 min), L-Ala (1.14 min), D-Ala 
(1.61 min), L-Phe (3.58 min), D-Phe (5.04 min), L-Leu (3.77 min), D-Leu (5.49 min), comparable to the 
observed retention times from the solonamide-derived amino acids.  
To specify the stereochemistry of enantiomeric amino acids, the depsipeptides were reduced by 
LiBH4. The resulting linear peptides were subjected to the above mentioned acid hydrolysis and 
Marfey’s derivatisation. Details are given in the Supplementary Information.  
For the absolute configuration of the fatty acid residues, the (R)- and (S)-Mosher’s esters were 
prepared for both depsipeptides, and the stereocenters were assigned based on their 1H and 19F chemical 
shift differences (ΔδSR) [76,77]. Details are given in the Supplementary Information.  
Solonamide A: white amorphous solids; UV (MeCN/H2O) λmax 200 nm (100%); for NMR data refer 
to Table 1; HRESIMS m/z 558.3486 (calcd for C30H46N4O6, 558.3496).  
Solonamide B: white amorphous solids; UV (MeCN/H2O) λmax 200 nm (100%); for NMR data refer 
to Table 1; HRESIMS m/z 586.3725 (calcd for C32H50N4O6, 586.3730).  
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Table 1. NMR spectroscopic data (DMSO-d6) of solonamide A and B. 
 A B 
 Atom δC (ppm) δH (ppm)(multiplicity, J (Hz)) HMBC Atom δC (ppm) δH (ppm)(multiplicity, J (Hz)) HMBC 
Hha/Hoa 
1 170.6 -  1 170.4 - - 
2 40.7 2.67 (1H, dd, 13.5, 3.8) 
2.11 (1H, dd, 13.5, 10.1) 
1,3,4 2 40.5 2.69 (1H, dd, 13.5, 3.7) 
2.11 (1H, dd, 13.5, 10.3) 
1,3,4 
3 72.1 5.14 (1H, m) 1,5 3 72.0 5.13 (1H, m) 1,4,5,36 
4 36.2 1.62 (1H, m) 
1.45 (1H, m) 
2,3,6 4 33.8 1.65 (1H, m) 
1.45 (1H, m) 
5,6 
5 17.7 ~1.22 (1H, m) 3,4 5 23.8 ~1.20 (2H, m) 6,7 
6 13.8 0.85 (3H, t, 7) 4,5 6 30.8 ~1.22 (2H, m) ND 
    7 21.8 1.25 (2H, m) ND 
    8 13.6 0.84 (3H, m) 6 
L-Phe 
7-NH - 8.61 (1H, d, 3.2) 1 9-NH - 8.59 (1H, d, 3.0) 1,10,11,8 
8-CHα 55.9 4.26 (1H, ddd, 10, 6.1, 3.2) 9,10,14 10-CHα 55.6 4.26 (1H, ddd, 10, 6.1, 3.3) 11,18 
9-CHβ,1 36.4 2.94 (1H, dd, 13.3, 6.1) 
2.72 (1H, dd, 13.3, 10) 
8,10,11/15,14 11-CHβ,1 36.1 2.95 (1H, dd, 13.3, 6.1) 
2.73 (1H, dd, 13.3, 10) 
10,12,13/17,18 
10 135.8 - - 12 136.0 - - 
11,15 129.1 7.18 (2H, m) 9,13 13,17 128.7 7.20 (2H, m) 11,15 
12,14 128.4 7.25 (2H, m) 10 14,16 128.0 7.26 (2H, m) 12,14/16 
13 126.5 7.18 (1H, m) 11 15 126.2 7.20 (1H, m) 13/17 
16-CO 174.4 - - 18-CO 174.2 - - 
D-Leu 
17-NH - 8.63 (1H, d, 5.6) 16,18,19 19-NH - 8.64 (1H, d, 5.6) 18,20,21 
18-CHα 53.1 3.56 (1H, m) ND 20-CHα 52.7 3.57 (1H, m) 21,22,25 
19-CHβ,1 38.9 1.36 (1H, m) 
1.29 (1H, m) 
18,21,22 21-CHβ,1 38.6 1.31–1.37 (2H, m) 20,22,24 
20-CHγ 23.5 0.97 (1H, m) 21 22-CHγ 23.3 0.99 (1H, m) ND 
21-CHδ,1 23.2 0.69 (3H, d, 6.6) 19,20 23-CHδ,1 22.9 0.70 (3H, d, 6.6) 21,22,24 
22-CHδ,1 20.7 0.52 (3H, d, 6.5) 19,20 24-CHδ,1 20.4 0.53 (3H, d, 6.4) 21,23 
23-CO 171.8 - - 25-CO 171.6 - - 
D-Ala 
24-NH - 7.53 (1H, d, 8.9) 27,29 26-NH - 7.48 (1H, d, 8.9) 25,27,28 
25-CHα 48.2 4.18 (1H, m) 26,27 27-CHα 47.8 4.18 (1H, m) 28,29 
26-CHβ,1 16.6 1.32 (3H, d, 7.4) 27 28-CHβ,1 16.4 1.33 (3H, d, 7.3) 27,29 
27-CO 171.3 - - 29-CO 170.9 - - 
L-Leu 
28-NH - 7.08 (1H, d, 10) 27,29 30-NH - 7.05 (1H, d, 10) 29,31 
29-CHα 49.0 4.46 (1H, dt, 10, 4.4) 30,31,34 31-CHα 48.6 4.47 (1H, dt, 10, 4.3) 32,33,29/36 
30-CHβ,1 39.3 1.63 (1H, m) 
1.53 (1H, m) 
29,31,33,27/34 32-CHβ,1 39.0 1.64 (1H, m) 
1.52 (1H, m) 
31,33,35,29/36 
31-CHγ 23.9 1.50 (1H, m) 29,30,33 33-CHγ 23.8 1.50 (1H, m) 32,34,35 
32-CHδ,1 23.2 0.86 (3H, d, 6.5) 30,31,33 34-CHδ,1 23.0 0.86 (3H, d, 6.6) 32,33,35 
33-CHδ,1 21.3 0.81 (3H, d, 6.5) 30 35-CHδ,1 21.1 0.82 (3H, d, 6.4) 32,33 
34-CO 171.2 - - 36-CO 170.8 - - 
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3.4. LC-UV/MS Analyses of Related Photobacterium Strains 
To investigate the potential production of agr inhibitors in related Photobacterium strains, the 
metabolite profile of S2753 was compared by liquid chromatography-diode array/mass spectrometry 
(LC-UV/MS) to P. halotolerans (LMG 22194T), P. rosenbergii (LMG 22223T), and P. angustum (S14) 
described by de Nys et al. [52]. All strains were grown in 30 mL MMM containing 0.4% glucose and 
0.3% casamino acids (25 °C, 72 h, 200 rpm). Cultures were extracted with an equal volume of EtOAc 
and evaporated under nitrogen. Residues were redissolved in MeOH for LC-UV/MS analyses and in 
80% EtOH for bioassay testing. Inhibition of agr was tested as described above. Extracts were also 
tested against V. anguillarum strain 90-11-287 for growth inhibition. LC-UV/MS analyses were 
performed on an Agilent 1100 liquid chromatograph with a diode array detector (Agilent, Waldbronn, 
Germany) coupled to an LCT TOF mass spectrometer (Micromass, Manchester, UK) using a Z-spray 
ESI source. Separation was obtained on a Luna II C18 column (50 × 2 mm, 3 μm, Phenomenex) fitted 
with a security guard system using a linear gradient starting from 15% MeCN in water (both buffered 
with 20 mM formic acid) increasing to 100% MeCN over 20 min at a flow rate of 0.3 mL min−1. 
3.5. Northern Blot Analysis 
Northern blot analysis was performed as described previously [78]. The strains used were S. aureus 
FPR 3757 [55], a CA-MRSA USA300 obtained from ATCC (Boras, Sweden), and 8325-4 [17]. Samples 
for RNA purification were taken from cultures in Tryptone Soya Broth (TSB, Oxoid, Greve, Denmark) 
shaking at 185 rpm at 37 °C in a water bath (10 mL culture in 100 mL Erlenmeyer flask). Growth was 
monitored by measuring optical density at OD600. Start inoculum was OD600 = 0.03. Solonamides were 
added at OD600 = 0.4. Samples for RNA purification were taken at OD600 = 0.7 and 1.7. Probes 
targeting rnaIII, spa, and hla transcripts were amplified by PCR using primers hla forward (5′-GGG 
TTA GCC TGG CCT TCA GCC-3′), hla reverse (5′-GGG TGC CAT ATA CCG GGT TC-3′),  
spa forward (5′-GGG GGT GTA GGT ATT GCA TCT G-3′), spa reverse (5′-GGG GCT CCT GAA 
GGA TCG TC-3′), rnaIII forward (5′-GGG GAT CAC AGA GAT GTG ATG-3′), and rnaIII reverse 
(5′-GGG CAT AGC ACT GAG TCC AAG G-3′)(TAG Copenhagen A/S, Denmark). The resulting 
PCR fragments were 311 bp (hla), 719 bp (spa), and 316 bp (rnaIII), respectively.  
4. Conclusions  
The rapid, worldwide increase in antibiotic-resistant S. aureus [15] has led to an intense search for 
compounds with potential use in alternative therapeutic strategies [9]. Virulence of S. aureus involves 
a complex set of proteins, with the agr QS system controlling expression of several of the virulence 
genes. The investigation of crude extracts and fractions from a marine Photobacterium led to the 
identification of two novel depsipeptides, solonamides A and B, as potent inhibitors of this system. 
Interestingly, we found that solonamide B interfered with agr not only in S. aureus 8325-4 but also in 
strain USA300, which is a predominant community-acquired MRSA (CA-MRSA) strain in the US [79]. 
This finding suggests that quorum sensing inhibition could be an option for treatment of S. aureus 
USA300 infections. Future experiments will reveal the extent to which the solonamides are effective in 
treating S. aureus infections. In combination with other recent work from our laboratory [42,45,71]  
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the present study underlines that vibrios are a promising potential source of novel bioactive 
secondary metabolites.  
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